Telemedicine company Hims & Hers Health Inc. (NYSE: HIMS) announced that its service platform will expand its product range to include Novo Nordisk's Wegovy® (semaglutide) oral tablets and injections, as well as Ozempic® injections.

These two drugs are both GLP-1 receptor agonists, mainly used for weight management and treatment of type 2 diabetes. **The Competitive Landscape of Weight Loss Drugs is Changing** The introduction of Wegovy and Ozempic marks Hims & Hers’ official entry into the rapidly expanding GLP-1 weight loss drug market. According to Bloomberg Intelligence, the global GLP-1 drug market is expected to exceed $150 billions by 2030. Novo Nordisk and Eli Lilly currently dominate this market, but the entry of telemedicine platforms may alter the competitive dynamics of drug distribution channels. Previously, Hims & Hers primarily offered hair care, skin health, and mental health services; this expansion is an important step toward chronic disease management. **Telemedicine Channel Advantages Stand Out** By combining prescription drugs with remote consultations, Hims & Hers can provide patients with more convenient access to medication. Users can complete online consultations on the platform and receive direct drug delivery services. This model is particularly suitable for chronic disease patients who require long-term medication, avoiding the waiting time and geographic limitations of traditional offline visits. However, GLP-1 drugs carry certain risks of side effects, such as gastrointestinal reactions, and must be used under medical supervision. The platform stated it will equip professional medical teams to evaluate and track users’ medication management. **Industry Competition and Regulatory Attention** As demand for weight loss drugs surges, the U.S. Food and Drug Administration (FDA) has strengthened regulation of GLP-1 drug prescriptions and usage. Some online pharmacies have come under scrutiny for simplifying prescription processes. Hims & Hers emphasizes that its services will strictly adhere to clinical guidelines to ensure medication safety. Meanwhile, peer companies such as Ro and Lemonaid Health have also begun offering similar services, but Hims & Hers’ large-scale user base may give it a first-mover advantage. **Market Impact and Future Outlook** After the announcement, Hims & Hers’ stock price rose slightly in pre-market trading. JPMorgan analysts pointed out that telemedicine platforms entering GLP-1 drug distribution could further increase industry penetration, but attention must be paid to regulatory policy changes and supply chain stability. If Hims & Hers can effectively integrate drug services with its existing health management programs, both user stickiness and per-customer value are expected to rise.